PLUS1
2.09
-0.03 (-1.42%)
-0.03 (-1.42%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Phio Pharmaceuticals Corporation | PHIO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.03 | -1.42% | 2.09 | 16:38:44 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 2.115 | 2.10 | 2.16 | 2.12 | 2.12 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 2.09 | 2.22 | 0.13 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 185 | 38,476 | $ 2.12 | $ 81,591 | 317,176 | 0.097 - 10.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:50:07 | 15 | $ 2.09 | USD |
Phio Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 12.08M | 5.78M | 5.75M | $ 21.00k | $ - | -19.23 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Phio Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/13/2020 | 16:31 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/28/2020 | 17:01 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) |
| 8/28/2020 | 17:01 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) |
| 8/19/2020 | 17:00 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/12/2020 | 17:05 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/12/2020 | 17:01 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 7/20/2020 | 17:15 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PHIO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.27 | 2.38 | 2.07 | 2.17 | 118,387 | -0.18 | -7.93% |
| 1 Month | 2.48 | 2.51 | 1.98 | 2.19 | 123,886 | -0.39 | -15.73% |
| 3 Months | 2.50 | 3.17 | 1.91 | 2.49 | 365,917 | -0.41 | -16.4% |
| 6 Months | 1.84 | 6.48 | 1.65 | 2.72 | 867,997 | 0.25 | 13.59% |
| 1 Year | 0.22 | 10.85 | 0.097 | 1.60 | 927,948 | 1.87 | 850.0% |
| 3 Years | 0.39 | 10.85 | 0.097 | 1.27 | 671,327 | 1.70 | 435.9% |
| 5 Years | 0.39 | 10.85 | 0.097 | 1.27 | 671,327 | 1.70 | 435.9% |
Phio Pharmaceuticals Description
| Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others. |
